Updated on 17 October 2012
Given the background, Asian countries and companies are not doing too badly at it. At this point, it is tough to imagine and name a few companies that can compete with the likes of Amgen, which currently has market capitalization in the range of $60 billion plus but the turn of this decade might just deliver a blockbuster therapy from the area. And it might even come from a company of Asian origin.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
